Insider Selling: Hims & Hers Health (NYSE:HIMS) Insider Sells 7,573 Shares of Stock

by · The Cerbat Gem

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) insider Irene Becklund sold 7,573 shares of the company’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $30.25, for a total value of $229,083.25. Following the transaction, the insider directly owned 11,280 shares in the company, valued at approximately $341,220. The trade was a 40.17% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Irene Becklund also recently made the following trade(s):

  • On Wednesday, June 17th, Irene Becklund sold 4,490 shares of Hims & Hers Health stock. The shares were sold at an average price of $31.50, for a total transaction of $141,435.00.

Hims & Hers Health Stock Performance

HIMS traded up $0.50 during midday trading on Wednesday, hitting $31.97. 23,080,110 shares of the company traded hands, compared to its average volume of 30,466,682. The firm has a market capitalization of $7.40 billion, a PE ratio of -355.22, a price-to-earnings-growth ratio of 56.60 and a beta of 2.37. The company’s 50-day moving average is $25.87 and its 200 day moving average is $26.65. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $70.43. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The firm’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same quarter last year, the company earned $0.20 EPS. On average, research analysts expect that Hims & Hers Health, Inc. will post 0.04 EPS for the current year.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Flagship Harbor Advisors LLC bought a new position in shares of Hims & Hers Health in the fourth quarter worth about $28,000. Binnacle Investments Inc bought a new position in shares of Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Bogart Wealth LLC grew its stake in shares of Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the 1st quarter worth approximately $30,000. Finally, Greenline Wealth Management LLC bought a new stake in Hims & Hers Health during the 4th quarter worth approximately $36,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analyst Ratings Changes

HIMS has been the topic of several research analyst reports. Barclays reissued an “overweight” rating and set a $39.00 price target on shares of Hims & Hers Health in a report on Wednesday. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Leerink Partners increased their target price on Hims & Hers Health from $17.50 to $25.00 and gave the company a “market perform” rating in a report on Monday, March 16th. Evercore set a $24.00 target price on Hims & Hers Health in a report on Tuesday, February 24th. Finally, Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and three have assigned a Sell rating to the company. According to data from MarketBeat.com, Hims & Hers Health presently has a consensus rating of “Hold” and an average price target of $29.37.

Read Our Latest Stock Analysis on Hims & Hers Health

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

Featured Stories